Pharma Bearish 7

FDA Flags Misleading Cancer Drug Claims by ImmunityBio’s Patrick Soon-Shiong

· 3 min read · By Biotech Intelligence Brief Editorial
Share

Key Takeaways

  • The FDA has issued a formal warning to Dr.
  • Patrick Soon-Shiong, the billionaire founder of ImmunityBio, regarding misleading statements made about the company’s bladder cancer therapy, Anktiva.
  • The regulator flagged claims made during a podcast that suggested the drug could treat a broader range of cancers than its current approval allows.

Mentioned

FDA organization Patrick Soon-Shiong person ImmunityBio company IBRX ANKTIVA product

Key Intelligence

Key Facts

  1. 1FDA flagged statements made by Dr. Patrick Soon-Shiong on a podcast regarding the drug Anktiva.
  2. 2Anktiva is currently FDA-approved only for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
  3. 3The regulator deemed the claims misleading as they suggested unproven efficacy in other solid tumors.
  4. 4ImmunityBio received its initial FDA approval for Anktiva in April 2024 after a prior 2023 rejection.
  5. 5Soon-Shiong is the founder and executive chairman of ImmunityBio and owner of the Los Angeles Times.

Who's Affected

ImmunityBio
companyNegative
Patrick Soon-Shiong
personNegative
FDA
companyNeutral

Analysis

The FDA’s public flagging of Dr. Patrick Soon-Shiong’s statements marks a significant regulatory rebuke for one of the biotech industry's most prominent and polarizing figures. The warning centers on promotional claims made by Soon-Shiong regarding Anktiva (nogapendekin alfa inbakicept-pmln), ImmunityBio’s recently approved immunotherapy for bladder cancer. By suggesting the drug possesses efficacy beyond its strictly defined label, Soon-Shiong has run afoul of federal misbranding regulations designed to prevent the promotion of off-label uses. This action by the FDA’s Office of Prescription Drug Promotion (OPDP) underscores a growing trend of regulatory scrutiny targeting high-profile executives who use informal media platforms to discuss clinical data.

Anktiva received FDA approval in April 2024 for use in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). This was a major milestone for ImmunityBio after a previous Complete Response Letter (CRL) in 2023. However, the FDA is notoriously strict regarding how executives discuss approved products, especially in public forums like podcasts where the line between personal optimism and corporate promotion often blurs. The regulator's intervention suggests that Soon-Shiong’s comments crossed the line from scientific discussion into unauthorized marketing, potentially misleading patients and healthcare providers about the drug's current capabilities.

While ImmunityBio is indeed studying Anktiva in other indications, such as lung cancer, the FDA maintains that presenting these experimental uses as current capabilities is misleading.

The specific claims made by Soon-Shiong reportedly implied that Anktiva's mechanism—activating natural killer (NK) cells and T-cells—could be a universal solution for various solid tumors. While ImmunityBio is indeed studying Anktiva in other indications, such as lung cancer, the FDA maintains that presenting these experimental uses as current capabilities is misleading. This incident echoes past controversies involving Soon-Shiong, who has often been criticized for science by press release and making grandiose claims about his Cancer Moonshot initiatives. The FDA’s move serves as a reminder that even for a drug with a novel mechanism of action, promotional claims must remain tethered to the data and indications specifically approved by the agency.

What to Watch

For ImmunityBio, this regulatory friction comes at a delicate time as the company scales the commercial launch of Anktiva. Regulatory warnings can dampen physician confidence and trigger increased scrutiny of all future marketing materials. Furthermore, such warnings can sometimes lead to shareholder litigation if investors feel they were misled by executive rhetoric. For the broader biotech sector, it serves as a stark reminder that the FDA's oversight extends to informal media like podcasts, webinars, and social media, not just traditional print advertisements or television commercials. Executives must exercise extreme caution when discussing the potential of their pipeline products in a way that could be interpreted as promoting off-label use of an approved drug.

Investors and industry analysts should monitor whether this leads to a formal Untitled Letter or a more severe Warning Letter that requires corrective advertising. The long-term value of ImmunityBio remains tied to its ability to expand Anktiva’s label through rigorous, peer-reviewed clinical trials rather than executive rhetoric. The FDA’s move signals a low tolerance for hype-driven medicine in the oncology space, particularly when it involves complex immunotherapies that carry significant safety and efficacy considerations. Moving forward, the company will likely need to implement more stringent internal controls over public communications from its leadership to avoid further regulatory entanglements.

Timeline

Timeline

  1. Initial Rejection

  2. FDA Approval

  3. Regulatory Warning

Cite This Page

"FDA Flags Misleading Cancer Drug Claims by ImmunityBio’s Patrick Soon-Shiong." Biotech Intelligence Brief, March 24, 2026. https://getbiobrief.com/story/fda-warning-immunitybio-patrick-soon-shiong-anktiva

Related Stories

Pharma

49-Year Species Rule Ends: Biotech’s Natural Drug Library Faces Extinction Risk

The U.S. Interior Department’s cancellation of automatic ESA protections for threatened species could accelerate biodiversity loss, directly threatening the natural sources of many pharmaceuticals. Bioprospecting and natural product R&D face heightened uncertainty as habitat destruction outpaces species discovery. The rule change adds regulatory complexity for biotech companies seeking access to rare organisms.

Pharma

Only 92 Deals: Big Pharma's TrumpRx Offering Covers Under 12% of Its 800+ Drug Stable

TrumpRx, the Trump administration's drug discount website, has secured voluntary pricing deals on only 92 brand-name drugs—less than 12% of the 800-plus products from 17 major pharmaceutical companies. High-cost therapies for inflammatory diseases, HIV, and cancer are largely excluded, raising doubts about industry's willingness to compromise on pricing without legislation.

Pharma

5,100 Suspected Cyclospora Cases Drive Demand for Rapid Diagnostics and New Therapies

The CDC's health alert on a cyclosporiasis outbreak with 5,100 suspected cases presents urgent needs in the biotech sector for rapid diagnostics, antiparasitic drug development, and food safety technologies. The parasite Cyclospora cayetanensis, with its long incubation period, challenges traditional detection methods, while treatment relies on a decades-old antibiotic. Innovators could capitalize on multiplex PCR panels and next-generation sequencing for outbreak tracking.

Pharma

Novartis, Roche Face 50% PBS Price Cut on MS Drugs as Briumvi Triggers Review

A July 2026 Australian PBS review for Roche's Ocrevus and Novartis’s Kesimpta could reduce government reimbursement by up to 50%, triggered by reference pricing with new low-cost entrant Briumvi. Manufacturers risk margin erosion or market withdrawal.

From the Network

Legal

FDA Sanctions Patrick Soon-Shiong Over Misleading Cancer Drug Claims

The FDA has issued a formal warning to billionaire Patrick Soon-Shiong regarding misleading promotional statements about ImmunityBio’s bladder cancer treatment. The regulatory action highlights a grow

How we covered this story

Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.

Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.

Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.

Signal on this pageWhat it tells you
Verified by N sourcesIndependent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly.
Impact score (1-10)Regulatory + financial + operational weight. 8+ signals an experienced-operator action item.
SentimentFive-tier classification trained on labeled biotech-specific corpora.
TimelineWhere applicable, the related-events sequence that contextualizes today's development.